Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorigerlimab in Advanced Solid Tumors (PROC and CCGC)
NCT06730347Phase 2Recruiting
- Sponsor
- MacroGenics
- Start
- May 2025
- Primary completion
- Jul 2027
- Countries
- 3
01
Overview
A Phase 2 trial of lorigerlimab in ovarian cancer, fallopian tube carcinoma (PFTC), primary peritoneal carcinoma (PPC), clear cell adenocarcinoma (CCA), endometrial cancer (EC), sponsored by MacroGenics. Started May 2025; status: recruiting.
02
Drugs
lorigerlimab
03
Conditions
ovarian cancerfallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)clear cell adenocarcinoma (CCA)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06730347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06730347.